multiple-sclerosis

Documents about multiple-sclerosis

• Metabolomic Signatures of Brain Atrophy and Ibudilast Response in Progressive Multiple Sclerosis#307238bioRxiv / medRxiv
• Autonomic reactivity to stress in multiple sclerosis: A meta-analytic review#384750HAL (France)
• Sensor-based Quantitative Assessment of Sensorimotor Deficits in Multiple Sclerosis#456851IRIS
• Genetic-Proteomic Integration Identifies Predictive Plasma Proteins for Multiple Sclerosis#642366Europe PMC
• Evaluation of Natalizumab for thE Relief of MS Associated FatiGue#800416ClinicalTrials.gov
• Muscle Vibration and Fatigue in Patients With MS#810818ClinicalTrials.gov
• Running Title: Walking to Music and in Silence on a Treadmill#846313ClinicalTrials.gov
• Lifestyle Weight Management Program: Interviews and Stakeholder Meetings.#888763ClinicalTrials.gov
• Acceptance Based Telephone Support When Transitioning to SPMS#889573ClinicalTrials.gov
• Drug Risk Aversion Calculator Use to Facilitate MS Patient Self-efficacy#900283ClinicalTrials.gov
• Sonification Techniques for Gait Training#909759ClinicalTrials.gov
• MSpine: a prospective longitudinal study of spinal cord lesions in multiple sclerosis: MRI monitoring and prognostic factors for active disease. A study protocol#123264Europe PMC
• Protocol for a pilot effectiveness and feasibility randomized controlled trial of an advanced telerehabilitation system for people with multiple sclerosis (PLATINUMS project)#474171ULRR
• Evaluation of Muscle Oxidative Capacity Relationship With Muscular Endurance, Fatigue (Multiple Sclerosis).#841434ClinicalTrials.gov
• BetaPlus Survey - Observational Study to Assess Drug Adherence in Patients With Multiple Sclerosis After Conversion to Betaferon® by Using Elements of the BetaPlus Program#884550ClinicalTrials.gov
• An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Fumarate-based RMS Approved Therapies or Fingolimod to Ofatumumab#887326ClinicalTrials.gov
• Efficacy, Safety and Tolerability of Atorvastatin 40 mg in Patients With Relapsing-remitting Multiple Sclerosis Treated With Interferon-beta-1b#902631ClinicalTrials.gov
• Extensive peripheral immunoglobulin repertoire analyses in people with multiple sclerosis reveal disease-specific signatures and distinct treatment effects of disease modifying drugs#123282Europe PMC
• Association of Peripapillary Retinal Nerve Fibre Layer Thickness with Disability and MRI Findings in Multiple Sclerosis: A Retrospective Single-Centre Cohort Study#231277Europe PMC
• An Exploratory Study to Evaluate Attention Biases in Adults With Multiple Sclerosis, Breast Cancer, and Lung Cancer#807759ClinicalTrials.gov
• Remyelination in Multiple Sclerosis: a PET-MR Longitudinal Study Investigating Individual Profiles of Myelin Repair and the Contribution of Neuroinflammation#828692ClinicalTrials.gov
• Open Label Randomized Multicenter to Assess Efficacy & Tolerability of Ofatumumab 20mg vs. First Line DMT in RMS#876618ClinicalTrials.gov
• Effects of the Cross-Training in Patients With Multiple Sclerosis#885201ClinicalTrials.gov
• Caracterización del perfil lipídico en pacientes en tratamiento para la esclerosis múltiple#367167Gestión del Repositorio Documental de la Universidad de Salamanca
• Applying an Ethical Lens to the Treatment of People With Multiple Sclerosis.#9011NCBI PubMed Central
• Brain Age Estimation on T2-FLAIR Scans for Application to Multiple Sclerosis.#14864NCBI PubMed Central
• Predicting disease progression in multiple sclerosis with clinically accessible information and technology.#122997NCBI PubMed Central
• MicroRNA-mRNA Regulatory Network Associated with Cognitive Impairment in Multiple Sclerosis.#149940NCBI PubMed Central
• Factors associated with delays in multiple sclerosis disease-modifying therapy initiation.#172129NCBI PubMed Central
• Genetic Determinants of Multiple Sclerosis Susceptibility in People From Diverse Ancestral Backgrounds#218169HAL (France)
• Ultra-low-field MRI for bedside imaging of severe multiple sclerosis.#262948NCBI PubMed Central
• Nurse-Led Digital Interventions for Patients with Multiple Sclerosis: A Scoping Review.#317798NCBI PubMed Central
• Steps to Health: Backward Walking Predicts Physical Activity Levels in Multiple Sclerosis.#380918NCBI PubMed Central
• The multifactorial nature of reproductive decision-making among women with multiple sclerosis.#636192NCBI PubMed Central
• The art of sequencing disease-modifying therapies in multiple sclerosis#661843Deutsche Nationalbibliothek
• Altered Glutamate Homeostasis in Paramagnetic Rim Lesions of Patients with Multiple Sclerosis#663847bioRxiv / medRxiv
• Physical and Cognitive Performance During the Two First Years of Lemtrada Treatment#826450ClinicalTrials.gov
• Validation of the French Adaptation of the MSWDQ-23 Questionnaire#836202ClinicalTrials.gov
• PROFILE - Evaluation of QoL and PRO Outcomes in Patients Taking Fingolimod#860073ClinicalTrials.gov
• Home Exercise Telerehabiliation for MS#882247ClinicalTrials.gov
• OFSEP Very High Definition Cohort#890210ClinicalTrials.gov
• Cognitive-motor Telerehabilitation in MS#917679ClinicalTrials.gov
• Tensor-derived diffusion MRI metrics and NODDI in multiple sclerosis classification.#923603NCBI PubMed Central
• Impact of reflex locomotion and the Bobath concept on clinical and biomolecular parameters in people with multiple sclerosis: study protocol for a randomized controlled trial#287857Gestión del Repositorio Documental de la Universidad de Salamanca
• Role of ADA SNPs in Subjects With Relapsing Multiple Sclerosis (RMS)#853548ClinicalTrials.gov
• Safety and Brain Protection Effects of the Green Tea Extract Theaphenon 95% (95% Pure EGCG) in Multiple Sclerosis#893584ClinicalTrials.gov
• Age-dependent response to initial highly effective treatment in relapsing multiple sclerosis#384911IRIS
• Italian Delphi Consensus on Maternity Care in Multiple Sclerosis: Toward an Interdisciplinary Model of Care#476189IRIS
• This Study Involves a Positron Emission Tomography (PET) Scan Using a New Investigational Radioactive Tracer, [18F]-FZTA, to Detect Inflammation in the Brain. The Tracer Will be Tested in Healthy Younger Adults and Individuals With Multiple Sclerosis.#901793ClinicalTrials.gov
• Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS#890215ClinicalTrials.gov